Search Results - Lisa Sproat

  • Showing 1 - 7 results of 7
Refine Results
  1. 1
    CHK1 and WEE1 inhibition combine synergistically to enhance therapeutic efficacy in acute myeloid leukemia ex vivo

    CHK1 and WEE1 inhibition combine synergistically to enhance therapeutic efficacy in acute myeloid leukemia ex vivo by Leena Chaudhuri, Nicole D. Vincelette, Brian D. Koh, Ryan M. Naylor, Karen S. Flatten, Kevin L. Peterson, Andrew McNally, Ivana Gojo, Judith E. Karp, Ruben A. Mesa, Lisa Sproat, James M. Bogenberger, Scott H. Kaufmann, Raoul Tibes

    Published 2013
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  2. 2
    Genetic features and clinical outcomes of patients with isolated and comutated<i>DDX41</i>-mutated myeloid neoplasms

    Genetic features and clinical outcomes of patients with isolated and comutated<i>DDX41</i>-mutated myeloid neoplasms by Hassan B. Alkhateeb, Ahmad Nanaa, David S. Viswanatha, James M. Foran, Talha Badar, Lisa Sproat, Rong He, Phuong L. Nguyen, Dragan Jevremović, Mohamad E. Salama, Patricia T. Greipp, Naseema Gangat, Ayalew Tefferi, Mark R. Litzow, Abhishek A. Mangaonkar, Mithun Vinod Shah, Mrinal M. Patnaik, Aref Al‐Kali

    Published 2021
    Get full text
    Artigo
    Save to List
    Saved in:
  3. 3
    Allogeneic Hematopoietic Cell Transplant for HIV Patients with Hematologic Malignancies: The BMT CTN-0903/AMC-080 Trial

    Allogeneic Hematopoietic Cell Transplant for HIV Patients with Hematologic Malignancies: The BMT CTN-0903/AMC-080 Trial by Richard F. Ambinder, Juan Wu, Brent R. Logan, Christine M. Durand, Ryan K. Shields, Uday Popat, Richard F. Little, Deborah K. McMahon, Joshua C. Cyktor, John W. Mellors, Ernesto Ayala, Lawrence D. Kaplan, Ariela Noy, Richard J. Jones, Alan Howard, Stephen J. Forman, David Porter, Carlos Arce‐Lara, Paul Shaughnessy, Lisa Sproat, Shahrukh K. Hashmi, Adam Mendizabal, Mary M. Horowitz, Willis H. Navarro, Joseph Alvarnas

    Published 2019
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  4. 4
    Venetoclax and hypomethylating agent combination therapy in newly diagnosed acute myeloid leukemia: Genotype signatures for response and survival among 301 consecutive patients

    Venetoclax and hypomethylating agent combination therapy in newly diagnosed acute myeloid leukemia: Genotype signatures for response and survival among 301 consecutive patients by Naseema Gangat, Omer Karrar, Moazah Iftikhar, Kristen McCullough, Isla McKerrow Johnson, Maymona Abdelmagid, Mostafa Abdallah, Aref Al‐Kali, Hassan B. Alkhateeb, Kebede H. Begna, Abhishek A. Mangaonkar, Antoine N. Saliba, Mehrdad Hefazi, Mark R. Litzow, William J. Hogan, Mithun Vinod Shah, Mrinal M. Patnaik, Animesh Pardanani, Talha Badar, Hemant S. Murthy, James M. Foran, Jeanne Palmer, Lisa Sproat, Nandita Khera, Cecilia Y. Arana Yi, Ayalew Tefferi

    Published 2023
    Get full text
    Artigo
    Save to List
    Saved in:
  5. 5
    Venetoclax duration (14 vs. 21 vs. 28 days) in combination with hypomethylating agent in newly diagnosed acute myeloid leukemia: Comparative analysis of response, toxicity, and survival

    Venetoclax duration (14 vs. 21 vs. 28 days) in combination with hypomethylating agent in newly diagnosed acute myeloid leukemia: Comparative analysis of response, toxicity, and sur... by Omer Karrar, Maymona Abdelmagid, Masooma Shifa Rana, Moazah Iftikhar, Kristen McCullough, Aref Al‐Kali, Hassan B. Alkhateeb, Kebede H. Begna, Michelle A. Elliott, Abhishek A. Mangaonkar, Antoine N. Saliba, Mehrdad Hefazi, Mark R. Litzow, William J. Hogan, Mithun Vinod Shah, Mrinal M. Patnaik, Animesh Pardanani, Talha Badar, Hemant S. Murthy, James M. Foran, Jeanne Palmer, Lisa Sproat, Nandita Khera, Cecilia Y. Arana Yi, Ayalew Tefferi, Naseema Gangat

    Published 2023
    Get full text Get full text
    Carta
    Save to List
    Saved in:
  6. 6
    Factors associated with survival following allogeneic transplantation for myeloid neoplasms harboring TP53 mutations

    Factors associated with survival following allogeneic transplantation for myeloid neoplasms harboring TP53 mutations by Anmol Baranwal, Kimberly J. Langer, Vedavyas Gannamani, Danielle Rud, Alia Cibich, Caner Saygin, Mariam T. Nawas, Talha Badar, Mohamed A. Kharfan‐Dabaja, Ernesto Ayala, Vivek Roy, James M. Foran, Hemant S. Murthy, Madiha Iqbal, Jeanne Palmer, Lisa Sproat, Saurabh Chhabra, Nandita Khera, Mehrdad Hefazi, Abhishek A. Mangaonkar, William J. Hogan, Mark R. Litzow, Hassan B. Alkhateeb, Ayalew Tefferi, Chung Hoow Kok, Guru Subramanian Guru Murthy, Anand Patel, Ashish Bajel, Devendra Hiwase, Mithun Vinod Shah

    Published 2025
    Get full text
    Artigo
    Save to List
    Saved in:
  7. 7
    Mayo Genetic Risk Models for Newly Diagnosed Acute Myeloid Leukemia Treated With Venetoclax + Hypomethylating Agent

    Mayo Genetic Risk Models for Newly Diagnosed Acute Myeloid Leukemia Treated With Venetoclax + Hypomethylating Agent by Naseema Gangat, Azeem Elbeih, Nour Ghosoun, Kristen McCullough, Fnu Aperna, Isla McKerrow Johnson, Maymona Abdelmagid, Aref Al‐Kali, Hassan B. Alkhateeb, Kebede H. Begna, Michelle A. Elliott, Abhishek A. Mangaonkar, Aasiya Matin, Antoine N. Saliba, Mehrdad Hefazi, Mark R. Litzow, William J. Hogan, Mithun Vinod Shah, Mrinal M. Patnaik, Animesh Pardanani, Talha Badar, Hemant S. Murthy, James M. Foran, Jeanne Palmer, Lisa Sproat, Nandita Khera, Cecilia Y. Arana Yi, Samuel J. Yates, Abigail Sneider, Emily Dworkin, Anand Patel, Alexandre Bazinet, Jayastu Senapati, Álex Bataller, Courtney D. DiNardo, Tapan M. Kadia, Ayalew Tefferi

    Published 2024
    Get full text Get full text
    Artigo
    Save to List
    Saved in:

Search Tools: